Premium
Plasma α‐synuclein in patients with Parkinson's disease with and without treatment[Note a. a Significant versus control group (P < 0.001). ...]
Author(s) -
Duran Raquel,
Barrero Francisco J.,
Morales Blas,
Luna Juan D.,
Ramirez Manuel,
Vives Francisco
Publication year - 2010
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22928
Subject(s) - alpha synuclein , parkinson's disease , pathogenesis , alpha (finance) , medicine , degenerative disease , central nervous system disease , endocrinology , disease , gastroenterology , surgery , construct validity , patient satisfaction
Alpha‐synuclein (α‐syn) is an intracellular protein with a high tendency to aggregation. It is the major component of Lewy bodies and may play a key role in the pathogenesis of Parkinson's disease (PD). α‐Syn is also released by neurons and can be detected in biological fluids, such as plasma. The purpose of this study was to determine whether plasma α‐syn concentrations are elevated in newly diagnosed PD patients before treatment (nontreated PD group, ntPD; n = 53) and to compare them with concentrations in PD patients with at least 1 year of specific treatment (tPD; n = 42) and in healthy controls (n = 60). Plasma α‐syn concentrations in the ntPD and tPD groups were similar and significantly higher than in healthy controls. In conclusion, α‐syn was elevated early in the development of PD and specific PD treatment did not change plasma α‐syn levels. © 2010 Movement Disorder Society